Pegvisomant
GH Axis / ClinicalAlso known as: Somavert
Mechanism
The opposite of growth hormone therapy — pegvisomant blocks the GH receptor instead of activating it. Used for acromegaly (excess GH production, usually from a pituitary tumor) when surgery and somatostatin analogs fail. It's a modified GH molecule that binds the receptor but can't activate it, like a key that fits the lock but won't turn. Normalizes IGF-1 levels in over 90% of patients.
Technical detail
PEGylated GH receptor antagonist. Structure: mutant GH analog with 8 amino acid substitutions — key mutation G120K in binding site 2 prevents functional GHR dimerization (GH normally crosslinks two GHR molecules; pegvisomant binds the first GHR via site 1 but the G120K mutation prevents productive engagement of the second GHR). Additional mutations in site 1 increase GHR binding affinity (H18D, H21N, R167N, K168A, D171S, K172R, E174S, I179T). Conjugated with 4-5 PEG (5 kDa) polymers to reduce immunogenicity and extend half-life to ~74 hours (vs. ~3 hours for native GH). Mechanism: competitive antagonist at GHR — blocks GH-induced JAK2/STAT5b signaling → reduces hepatic IGF-1 synthesis. Does NOT suppress GH secretion (GH levels actually increase 2-3x due to loss of IGF-1 negative feedback). Efficacy: normalizes IGF-1 in 63% (monotherapy trials) to 97% (with dose titration) of acromegaly patients. Dosing: 40mg SC loading dose, then 10-30mg SC daily, titrated to IGF-1 normalization. Key monitoring: liver function (transaminase elevations in ~5-10%, usually mild and reversible). Theoretical concern: pituitary tumor growth from loss of IGF-1 feedback (monitor with MRI), but clinical data reassuring. Can be combined with somatostatin analogs for synergistic effect.
Effects
ENDOCRINE SYSTEM (GH AXIS): Pegvisomant is a PEGylated recombinant human growth hormone analog that functions as a GH receptor (GHR) antagonist. Eight amino acid substitutions (key: G120K) prevent the conformational change required for functional GHR dimerization — pegvisomant binds the GHR at site 1 but blocks productive signaling at site 2 [pharmacological — Kopchick et al.]. PEGylation (4-6 PEG moieties of 5kDa each) extends half-life and reduces immunogenicity [pharmacokinetic]. MECHANISM: GH normally binds two GHR molecules sequentially (site 1, then site 2), triggering JAK2/STAT5 signaling and IGF-1 production. Pegvisomant binds site 1 with normal affinity but the G120K substitution prevents proper site 2 engagement, creating a non-functional dimer that cannot signal [in vitro, crystallographic]. Result: dose-dependent suppression of hepatic IGF-1 production without affecting GH secretion (GH levels actually increase due to loss of IGF-1 negative feedback) [RCT]. CLINICAL EFFECTS IN ACROMEGALY: Normalizes IGF-1 in approximately 90-97% of patients at adequate doses (vs. ~55-65% for somatostatin analogs and ~35% for cabergoline) — the most effective medical therapy for acromegaly [RCT, registry data — ACROSTUDY]. Reduces acromegaly symptoms: soft tissue swelling, headache, joint pain, excessive sweating, fatigue [RCT]. Improves insulin sensitivity and glucose metabolism — unlike somatostatin analogs, which can worsen glycemic control, pegvisomant improves it (GH is diabetogenic, blocking GH improves insulin sensitivity) [RCT]. Does NOT shrink pituitary adenomas — it blocks peripheral GH action but does not address the tumor. GH levels rise (loss of IGF-1 feedback), and tumors may grow in ~3% of patients [clinical observation, registry data]. HEPATIC: Dose-dependent elevation of transaminases in 3-8% of patients, with rare cases of clinically significant hepatotoxicity [RCT, post-market surveillance]. Mechanism unclear — possibly direct hepatotoxic effect or immune-mediated [clinical observation]. METABOLIC: Improves lipid profiles — reduces LDL cholesterol and total cholesterol [clinical]. Can cause weight gain (removal of GH's lipolytic effect) [clinical].
Practitioner Guide
ADMINISTRATION: Subcutaneous injection, once daily. Self-administered by patients after training (similar to insulin). Available as Somavert® (Pfizer). DOSING: Loading dose: 40 mg SC. Maintenance: start at 10 mg SC daily. Titrate based on IGF-1 levels — target is age- and sex-normalized IGF-1 within the reference range. Increase by 5 mg increments every 4-6 weeks. Typical effective dose: 10-30 mg/day. Some patients require up to 40 mg/day. Maximum studied: 40 mg/day (higher doses used off-label in refractory cases). Dose adjustment guided by IGF-1 levels (NOT GH levels — GH will be elevated due to loss of feedback, and this is expected). MONITORING: IGF-1 levels every 4-6 weeks during titration, then every 6 months once stable. LFTs (AST, ALT): at baseline, monthly for first 6 months, then quarterly. If transaminases >3x ULN: reduce dose. If >5x ULN or with symptoms: discontinue. Pituitary MRI: every 6-12 months initially (monitor tumor size — GH rise may stimulate growth in ~3%). GH levels: measure but do NOT use to guide dosing (they will be elevated, this is expected and not harmful). Glucose/HbA1c: monitor improvement in diabetic/pre-diabetic patients (may need to reduce diabetic medications). COMBINATION THERAPY: Can combine with somatostatin analogs (octreotide, lanreotide) — the SSA controls tumor size while pegvisomant normalizes IGF-1. This combination is particularly useful for patients with large or growing tumors. Some centers use pegvisomant + cabergoline for cost reduction (lower pegvisomant doses needed). PRACTICAL TIPS: Injection site rotation important — lipohypertrophy can occur at repeated injection sites (reduces absorption). Reconstitute with provided diluent, gently swirl (do NOT shake — protein denaturation). Room temperature for injection. Once reconstituted: use within 6 hours (no preservative in some formulations). COST CONSIDERATION: Extremely expensive — approximately $50,000-100,000+/year depending on dose. Prior authorization required. Patient assistance programs available. This is a major barrier to use. STORAGE: Refrigerate (2-8°C). Do not freeze. Protect from light. CONCEPTUAL IMPORTANCE IN PEPTIDE SPACE: Understanding pegvisomant is essential for anyone working with GH secretagogues (CJC-1295, Ipamorelin, GHRP-6, etc.) — it represents the antidote to excess GH signaling. Knowing how to block GH provides perspective on the risks of stimulating it: the same soft tissue growth, insulin resistance, and potential tumor effects that pegvisomant reverses are the potential consequences of excessive GH stimulation. CONTRAINDICATIONS: Hypersensitivity to pegvisomant. Latex allergy (vial stopper contains latex in some formulations). Caution in hepatic impairment. Not studied in pregnancy.
Evidence
- moderate
Xu et al. (2026) — Endocr Pract — PMID: 41933589
Cross-database pharmacovigilance analysis found reproducible pegvisomant safety-reporting patterns, with notable signals around hepatobiliary events, injection-site reactions, hypersensitivity, and administration-related issues; median FAERS time to onset was 164 days, highlighting the need for ongoing monitoring during therapy.
Research Summary
TIER 1: Pivotal RCT (Trainer et al., 2000 — NEJM): pegvisomant 10-20 mg/day normalized IGF-1 in 89-97% of acromegaly patients (dose-dependent). Phase III trials confirming efficacy and safety. ACROSTUDY — long-term international observational registry: >2,000 patients, >10 years of real-world data confirming sustained IGF-1 normalization in ~63-73% (lower than trials due to suboptimal dosing in practice), hepatotoxicity in ~3-8%, tumor growth in ~3%. FDA-approved 2003 (Somavert®). RCTs demonstrating improved glucose metabolism vs. somatostatin analogs. RCTs of combination therapy (pegvisomant + SSA). TIER 2: Systematic reviews and meta-analyses confirming pegvisomant as the most effective medical therapy for IGF-1 normalization in acromegaly (Neggers et al., 2011; van der Lely et al., 2012). Expert consensus guidelines (Acromegaly Consensus Group). Reviews of GH receptor biology and the structural basis of pegvisomant antagonism (Kopchick et al.). Cost-effectiveness analyses (generally favorable given disease burden, but absolute cost remains high). TIER 3: Case reports of pegvisomant in refractory acromegaly at high doses (>40 mg/day). Case series of hepatotoxicity — mostly reversible with dose reduction/discontinuation. International registry data from specialized pituitary centers. Off-label case reports exploring GH blockade in non-acromegaly contexts (diabetic retinopathy, some cancers). KEY FINDINGS: Pegvisomant is the most effective single agent for normalizing IGF-1 in acromegaly, with a well-characterized safety profile. The hepatotoxicity risk is manageable with monitoring. Its primary limitation is cost. Conceptually, it validates the GH receptor as a druggable target and provides the intellectual framework for understanding GH blockade alongside GH stimulation. GAPS: Limited data on very long-term outcomes (>15 years). Tumor growth risk not fully characterized (the GH rise is concerning theoretically). No head-to-head trials with newer somatostatin analogs (pasireotide). Off-label applications (diabetic complications, cancer) poorly studied. ACTIVE TRIALS: Ongoing long-term ACROSTUDY follow-up. Trials of pegvisomant in combination with pasireotide. Studies exploring biomarkers for hepatotoxicity risk. Investigator-initiated studies in diabetic retinopathy.